|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:available_in
|
gptkb:Australia
gptkb:Canada
gptkb:UK
gptkb:United_States
|
|
gptkbp:brand
|
gptkb:Aptensio_XR
|
|
gptkbp:class
|
gptkb:pharmaceuticals
|
|
gptkbp:clinical_trial
|
NCT02212345
NCT02212346
NCT02212347
|
|
gptkbp:condition
|
ADD
ADHD
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
heart problems
history of substance abuse
|
|
gptkbp:counseling_services
|
keep out of reach of children
do not crush or chew
monitor for mood changes
take as prescribed
report any heart problems
|
|
gptkbp:dosage_form
|
gptkb:capsule
|
|
gptkbp:drug_interactions
|
gptkb:warfarin
antidepressants
MAO inhibitors
antihypertensives
anticonvulsants
|
|
gptkbp:form
|
extended-release capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aptensio XR
|
|
gptkbp:ingredients
|
gptkb:Sannin
|
|
gptkbp:manufacturer
|
gptkb:Neos_Therapeutics
|
|
gptkbp:marketed_as
|
gptkb:2015
|
|
gptkbp:mechanism_of_action
|
inhibits reuptake of norepinephrine and dopamine
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:previous_name
|
gptkb:Sannin
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
anxiety
headache
nausea
decreased appetite
insomnia
|
|
gptkbp:storage
|
room temperature
away from moisture
away from heat
|
|
gptkbp:strength
|
15 mg
30 mg
22.5 mg
7.5 mg
3.75 mg
|
|
gptkbp:used_for
|
treatment of ADHD
|
|
gptkbp:bfsParent
|
gptkb:Sannin
|
|
gptkbp:bfsLayer
|
5
|